Christine Fox sold $98k of TEVA
EVP, Head of U.S. Commercial at TEVA PHARMACEUTICAL INDUSTRIES LTD. 6,181 shares at an average of $15.80, traded Mar 4, 2025, filed Mar 6, 2025.
Score components
- +15RoleOfficer
- +10Trade size$98k at market
- 0Share of holdings soldSold 9.6% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-034687, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 4, 2025 | MOption exercise Ordinary Shares10b5-1 | +20,461 | - | - | 64,565 | Mar 6, 2025 |
| Mar 4, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -4,034 | $15.73 | $63k | 60,531 | Mar 6, 2025 |
| Mar 5, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -2,147 | $15.91 | $34k | 58,384 | Mar 6, 2025 |
| Mar 4, 2025 | MOption exercise Restricted Share Unitsderivative10b5-1 | -20,461 | $0.00 | $0 | 61,384 | Mar 6, 2025 |
Related signals
Other insiders at TEVA PHARMACEUTICAL INDUSTRIES LTD and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 68Notable | TEVA PHARMACEUTICAL INDUSTRIES LTD | Roberto Mignone director | $14M 367,600 shares | -100% | |
| 32Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Brian Savage Interim Chief Legal Officer | $285k 7,342 shares | -46% | |
| 40Moderate | TEVA PHARMACEUTICAL INDUSTRIES LTD | Richard Daniell Exec. VP, European Commercial | $1.1M 70,961 shares | -59% | |
| 40Moderate | TEVA PHARMACEUTICAL INDUSTRIES LTD | Richard Daniell Exec. VP, European Commercial | $2.2M 140,372 shares | -419% | |
| 21Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Richard D Francis President and CEO | $376k 23,773 shares | -8% | |
| 30Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Eric A Hughes See "Remarks" | $367k 23,251 shares | -100% | |
| 40Moderate | TEVA PHARMACEUTICAL INDUSTRIES LTD | Richard Daniell Exec. VP, European Commercial | $999k 62,250 shares | -100% | |
| 28Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Richard D Francis President and CEO | $503k 31,342 shares | -11% | |
| 31Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Eric A Hughes See "Remarks" | $400k 24,900 shares | -100% | |
| 36Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Eliyahu Sharon Kalif EVP, Chief Financial Officer | $903k 55,750 shares | -27% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.